Lipocine Inc
NASDAQ:LPCN

Watchlist Manager
Lipocine Inc Logo
Lipocine Inc
NASDAQ:LPCN
Watchlist
Price: 9.46 USD -8.86% Market Closed
Market Cap: $52.5m

Net Margin

-126.7%
Current
Improving
by 2 205.9%
vs 3-y average of -2 332.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-126.7%
=
Net Income
$-5.5m
/
Revenue
$4.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-126.7%
=
Net Income
$-5.5m
/
Revenue
$4.3m

Peer Comparison

Country Company Market Cap Net
Margin
US
Lipocine Inc
NASDAQ:LPCN
51.3m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
972.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.5B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
272.1B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.8B EUR
Loading...

Market Distribution

Lower than 86% of companies in the United States of America
Percentile
14th
Based on 15 072 companies
14th percentile
-126.7%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Lipocine Inc
Glance View

Market Cap
52.5m USD
Industry
Pharmaceuticals

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 13 full-time employees. The company went IPO on 2014-03-21. The firm is focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. The company has a portfolio of product candidates that target unmet needs for neurological and psychiatric central nervous system (CNS) disorders, liver diseases, and hormone supplementation for men and women. The firm's product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its additional pipeline candidates include LPCN 1148, LPCN 1144, LPCN 1111 (TLANDO XR), LPCN 1107, LPCN 1154 and LPCN 2101. Its LPCN 1144 is an oral prodrug of bioidentical testosterone comprised of TU for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) which has completed Phase II testing. Its TLANDO XR is an oral TRT product comprised of testosterone tridecanoate (TT), which has completed Phase II trials.

LPCN Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-126.7%
=
Net Income
$-5.5m
/
Revenue
$4.3m
What is Lipocine Inc's current Net Margin?

The current Net Margin for Lipocine Inc is -126.7%, which is above its 3-year median of -2 332.6%.

How has Net Margin changed over time?

Over the last 3 years, Lipocine Inc’s Net Margin has decreased from 24.7% to -126.7%. During this period, it reached a low of -24 120% on Jun 30, 2023 and a high of 573.6% on Dec 31, 2023.

Back to Top